A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 734 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 January 15, 2021 “Nothing about us without us”: Why we’re working in partnership with... March 10, 2023 A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in... October 10, 2023 Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation June 5, 2024 Load more HOT NEWS New on NCI’s Websites, March 2020 “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of...
